ProCE Banner Activity

An Expert’s Guide to ASCO GI 2023: A Preview of the Top Abstracts

Conference Coverage
Clinical Thought

In this commentary, expert faculty highlight key studies being presented at the upcoming ASCO Gastrointestinal Cancers Symposium. CCO&rsquo s Independent Conference Coverage of ASCO GI 2023 will have the information you need to understand and integrate the latest oncology data into your clinical practice.

Released: January 19, 2023

Expiration: January 18, 2024

Share

Faculty

Christopher H. Lieu

Christopher H. Lieu, MD

Associate Professor
Associate Director for Clinical Research
Division of Medical Oncology
University of Colorado Cancer Center
Co-Director, GI Medical Oncology
Division of Medical Oncology
University of Colorado Hospital
Aurora, Colorado

Rachna Shroff

Rachna Shroff, MD, MS

Professor of Medicine
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Bristol Myers Squibb

Incyte Corporation

Merck Sharp & Dohme Corp.

Seagen Inc.

Faculty Disclosure

Primary Author

Christopher H. Lieu, MD

Associate Professor
Associate Director for Clinical Research
Division of Medical Oncology
University of Colorado Cancer Center
Co-Director, GI Medical Oncology
Division of Medical Oncology
University of Colorado Hospital
Aurora, Colorado

Christopher H. Lieu, MD: researcher: Merck.

Rachna Shroff, MD, MS

Professor of Medicine
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

Rachna Shroff, MD, MS: consultant/advisor/speaker: AstraZeneca, Boehringer Ingelheim, Clovis, Genentech, Incyte, Merck, QED Therapeutics, Servier, Taiho, Syros, Zymeworks Biopharm; researcher: Bayer, Bristol-Myers Squibb, Exelixis, IMV, LOXO, Merck, Novocure, Nucana, Pieris, QED Therapeutics, Rafael, Seagen, Taiho.